Meeting
2016 ASCO Annual Meeting
The impact of clinical stage at primary melanoma diagnosis on post-recurrence survival.
Authors
Kierstin Utter
New York University School of Medicine, New York, NY
Kierstin Utter , Brooke E Rosenbaum , Sung Won Han , Judy Zhong , Una Moran , Eleazar Vega-Saenz de Miera , Farbod Darvishian , David Polsky , Russell S. Berman , Richard L. Shapiro , Iman Osman , Anna C. Pavlick , Melissa Wilson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 34, 2016 (suppl; abstr 9550)
DOI
10.1200/JCO.2016.34.15_suppl.9550
Abstract #
9550
Poster Bd #
155
Abstract Disclosures
Similar Posters
First Author: Sara Moore
Poster
2021 ASCO Annual Meeting
Evaluation of patients with surgically resected high-risk melanoma receiving adjuvant therapy in routine clinical practice in the United States.
First Author: Michael B. Atkins
Poster
2021 ASCO Annual Meeting
Outcomes of BRAF mutant metastatic melanoma (MM) patients (pts) after cessation of targeted therapy (TT) with BRAF or BRAF/MEK inhibitor(i).
First Author: Natalie Jackson
Poster
2019 ASCO Annual Meeting
A sequential dual cohort phase II clinical trial on adjuvant low-dose nivolumab with or without low-dose ipilimumab as adjuvant therapy following the resection of melanoma macrometastases (MM).
First Author: Julia Katharina Schwarze